CytoSorbents Corp (CTSO)
1.50
+0.08
(+5.63%)
USD |
NASDAQ |
Sep 27, 16:00
1.48
-0.02
(-1.33%)
After-Hours: 20:00
CytoSorbents SG&A Expense (Annual): 37.87M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 37.87M |
| December 31, 2022 | 37.14M |
| December 31, 2021 | 38.48M |
| December 31, 2020 | 31.51M |
| December 31, 2019 | 24.47M |
| December 31, 2018 | 22.88M |
| December 31, 2017 | 16.25M |
| December 31, 2016 | 12.99M |
| December 31, 2015 | 8.012M |
| Date | Value |
|---|---|
| December 31, 2014 | 6.45M |
| December 31, 2013 | 3.485M |
| December 31, 2012 | 1.982M |
| December 31, 2011 | 1.573M |
| December 31, 2010 | 1.067M |
| December 31, 2009 | 1.065M |
| December 31, 2008 | 1.261M |
| December 31, 2007 | 1.651M |
| December 31, 2006 | 1.852M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
24.47M
Minimum
2019
38.48M
Maximum
2021
33.89M
Average
37.14M
Median
2022
SG&A Expense (Annual) Benchmarks
| Delcath Systems Inc | 22.11M |
| Star Equity Holdings Inc | 14.54M |
| Exact Sciences Corp | 1.620B |
| Illumina Inc | 1.612B |
| Progyny Inc | 176.62M |